United Laboratories Doses First Patient in Phase III China Trial of Triple-Agonist UBT251 for Overweight and Obesity

Bulletin Express09-04

Hong Kong-listed United Laboratories International Holdings Limited (United Laboratories) announced that its wholly owned subsidiary, The United Bio-Technology (Hengqing) Co., Ltd., has commenced dosing in a Phase III clinical trial of UBT251 Injection for adults with overweight or obesity in China.

The randomized, double-blind, placebo-controlled study will enroll 600 participants with body-mass index (BMI) ≥28.0 kg/m² (obesity) or 24.0–27.9 kg/m² (overweight) plus at least one weight-related comorbidity. Primary endpoints include: • Percentage change in body weight from baseline; • Proportion of participants achieving ≥5 % weight reduction after 52 weeks of treatment.

UBT251 is a long-acting, chemically synthesized triple-target receptor agonist of GLP-1, GIP and glucagon (GCGR). The molecule is under clinical development in China and/or the United States for multiple indications: adult type 2 diabetes, overweight or obesity, chronic kidney disease, metabolic dysfunction-associated steatohepatitis and moderate-to-severe obstructive sleep apnea with obesity. United Laboratories is the first company in China—and the second worldwide—to obtain clinical-trial approval for a long-acting GLP-1R/GIPR/GCGR triple agonist.

In March 2025, United Biotechnology and United Laboratories entered into an exclusive licensing agreement with Novo Nordisk A/S concerning UBT251.

The board, chaired by Mr. Tsoi Hoi Shan, disclosed the update on 4 September 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1188495699?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-04 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188495699","market":"us","top_or_hot":-1,"title":"United Laboratories Doses First Patient in Phase III China Trial of Triple-Agonist UBT251 for Overweight and Obesity","media":"Bulletin Express","content":"<p>Hong Kong-listed United Laboratories International Holdings Limited (United Laboratories) announced that its wholly owned subsidiary, The United Bio-Technology (Hengqing) Co., Ltd., has commenced dosing in a Phase III clinical trial of UBT251 Injection for adults with overweight or obesity in China.</p>\n<p>The randomized, double-blind, placebo-controlled study will enroll 600 participants with body-mass index (BMI) ≥28.0 kg/m² (obesity) or 24.0–27.9 kg/m² (overweight) plus at least one weight-related comorbidity. Primary endpoints include:\n• Percentage change in body weight from baseline;  \n• Proportion of participants achieving ≥5 % weight reduction after 52 weeks of treatment.</p>\n<p>UBT251 is a long-acting, chemically synthesized triple-target receptor agonist of GLP-1, GIP and glucagon (GCGR). The molecule is under clinical development in China and/or the United States for multiple indications: adult type 2 diabetes, overweight or obesity, chronic kidney disease, metabolic dysfunction-associated steatohepatitis and moderate-to-severe obstructive sleep apnea with obesity. United Laboratories is the first company in China—and the second worldwide—to obtain clinical-trial approval for a long-acting GLP-1R/GIPR/GCGR triple agonist.</p>\n<p>In March 2025, United Biotechnology and United Laboratories entered into an exclusive licensing agreement with Novo Nordisk A/S concerning UBT251.</p>\n<p>The board, chaired by Mr. Tsoi Hoi Shan, disclosed the update on 4 September 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>United Laboratories Doses First Patient in Phase III China Trial of Triple-Agonist UBT251 for Overweight and Obesity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnited Laboratories Doses First Patient in Phase III China Trial of Triple-Agonist UBT251 for Overweight and Obesity\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-04 19:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hong Kong-listed United Laboratories International Holdings Limited (United Laboratories) announced that its wholly owned subsidiary, The United Bio-Technology (Hengqing) Co., Ltd., has commenced dosing in a Phase III clinical trial of UBT251 Injection for adults with overweight or obesity in China.</p>\n<p>The randomized, double-blind, placebo-controlled study will enroll 600 participants with body-mass index (BMI) ≥28.0 kg/m² (obesity) or 24.0–27.9 kg/m² (overweight) plus at least one weight-related comorbidity. Primary endpoints include:\n• Percentage change in body weight from baseline;  \n• Proportion of participants achieving ≥5 % weight reduction after 52 weeks of treatment.</p>\n<p>UBT251 is a long-acting, chemically synthesized triple-target receptor agonist of GLP-1, GIP and glucagon (GCGR). The molecule is under clinical development in China and/or the United States for multiple indications: adult type 2 diabetes, overweight or obesity, chronic kidney disease, metabolic dysfunction-associated steatohepatitis and moderate-to-severe obstructive sleep apnea with obesity. United Laboratories is the first company in China—and the second worldwide—to obtain clinical-trial approval for a long-acting GLP-1R/GIPR/GCGR triple agonist.</p>\n<p>In March 2025, United Biotechnology and United Laboratories entered into an exclusive licensing agreement with Novo Nordisk A/S concerning UBT251.</p>\n<p>The board, chaired by Mr. Tsoi Hoi Shan, disclosed the update on 4 September 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03933","symbol_name":"联邦制药","start_time":0,"source_url":"","article_id":"1188495699","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188495699","pubTimestamp":1788519741,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hong Kong-listed United Laboratories International Holdings Limited (United Laboratories) announced that its wholly owned subsidiary, The United Bio-Technology (Hengqing) Co., Ltd., has commenced...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03933":"联邦制药"},"translate_title":"联邦制药在三重激动剂UBT251治疗跑赢大盘和肥胖症的III期中国试验中为首位患者注射药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03933":1},"content_text":"Hong Kong-listed United Laboratories International Holdings Limited (United Laboratories) announced that its wholly owned subsidiary, The United Bio-Technology (Hengqing) Co., Ltd., has commenced dosing in a Phase III clinical trial of UBT251 Injection for adults with overweight or obesity in China.\nThe randomized, double-blind, placebo-controlled study will enroll 600 participants with body-mass index (BMI) ≥28.0 kg/m² (obesity) or 24.0–27.9 kg/m² (overweight) plus at least one weight-related comorbidity. Primary endpoints include:\n• Percentage change in body weight from baseline;  \n• Proportion of participants achieving ≥5 % weight reduction after 52 weeks of treatment.\nUBT251 is a long-acting, chemically synthesized triple-target receptor agonist of GLP-1, GIP and glucagon (GCGR). The molecule is under clinical development in China and/or the United States for multiple indications: adult type 2 diabetes, overweight or obesity, chronic kidney disease, metabolic dysfunction-associated steatohepatitis and moderate-to-severe obstructive sleep apnea with obesity. United Laboratories is the first company in China—and the second worldwide—to obtain clinical-trial approval for a long-acting GLP-1R/GIPR/GCGR triple agonist.\nIn March 2025, United Biotechnology and United Laboratories entered into an exclusive licensing agreement with Novo Nordisk A/S concerning UBT251.\nThe board, chaired by Mr. Tsoi Hoi Shan, disclosed the update on 4 September 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1188495699","isCrawlerRequest":true}